# Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

> **NCT04722666** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 199 (actual)

## Conditions studied

- Major Depressive Disorder With Suicidal Ideation With Intent

## Interventions

- **DRUG:** MIJ821 Intravenous Injection
- **DRUG:** Placebo Intravenous Injection

## Key facts

- **NCT ID:** NCT04722666
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-20
- **Primary completion:** 2023-09-26
- **Final completion:** 2023-09-26
- **Target enrollment:** 199 (ACTUAL)
- **Why stopped:** Terminated by Novartis
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04722666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04722666, "Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04722666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*